Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age;~* Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);~* Anticoagulant treatment completed~* No recurrence of Venous Thromboembolism (VTE)~Exclusion Criteria:~* Subjects with indications for long-term treatment with a vitamin K antagonist~* Active bleeding or high risk for serious bleeding~* Short life expectancy~* Uncontrolled high blood pressure~* Impaired kidney or liver function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 2.5 mg
- 2 (Type: EXPERIMENTAL): 5.0 mg
- 3 (Type: ACTIVE_COMPARATOR): 0 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).